Today marks the first International NASH Day, to raise awareness for this disease and hopefully accelerates the discovery and development of better treatment solutions for millions of patients suffering from this debilitating condition. This groundbreaking event aims to motivate the public to learn more about this silent killer called NASH.
Biocellvia is a French startup which creates fully automated digital image analysis programs in order to help biotechs and big pharmas in the drug discovery process at the preclinical stage. This startup first began developing customized programs for respiratory diseases. Now, by leveraging their decades of expertise and experience, Biocellvia’s CEO and CSO decided to focus their resources to tackle this liver disease with an enormous unmet medical need, affecting large populations around the world.
Biocellvia’s Research & Development team has been focusing on NASH for the last 10 months. Our aim was to create a completely automated digital image analysis program in order to evaluate the efficacy of lead molecules against NASH and the level of disease severity by assessing different parameters.
This unique program will help research teams in biotechs and big pharmas obtain robust, quantitative, and allow them to better interpret their study results and make critical decisions on their compound candidates.
In recent years, NASH has quickly become a very serious public health issue. Experts estimate that this liver disorder affects approximately 20 percent of the U.S. population, and want to urge primary-care providers to send patients for testing earlier in diagnosis. Called nonalcoholic steatohepatitis, or NASH for short, it does not result from drug use, alcoholism, sexual contact, water contaminants or viruses. Rather, this particular liver condition occurs when too much fat is stored in liver cells. Currently, there is no approved therapies to cure patients inflicted by NASH.
Biocellvia is making an important contribution to tackle this grave public health challenge, by using its proprietary technology to support scientists to make better informed decisions to develop effective, affordable drugs for patients. By incorporating Biocellvia’s digital technology in their drug development process, pharmaceutical companies can drastically reduce the time and cost in their R&D process, because Biocellvia’s specialized programs can perform image analysis in a matter of hours, whereas traditionally the same manual work takes weeks or months.
To learn more about Biocellvia’s NASH digital automated programs, contact us.